HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information

Breast Cancer Research and Treatment

Volumn 109, Issue 2, 2008, Pages 351-357

  Rydén, Lisa ^a   Landberg, Göran ^b   Stål, Olle ^c   Nordenskjöld, Bo ^c   Fernö, Mårten ^a   Bendahl, Pär Ola ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Breast cancer; HER2 status; Prognosis; Tamoxifen; Treatment prediction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TISSUE ARRAY ANALYSIS;

EID: 43149123572     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9660-2     Document Type: Article

References (26)

1. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-712
2. Borg A, Tandon AK, Sigurdsson H et al (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337
3. Press MF, Bernstein L, Thomas PA et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15(8):2894-2904
4. Sjogren S, Inganas M, Lindgren A et al (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469
5. Schmidt M, Lewark B, Kohlschmidt N et al (2005) Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 7(2):R256-266
6. Joensuu H, Isola J, Lundin M et al (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9(3):923-930
7. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
8. Kun Y, How LC, Hoon TP et al (2003) Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet 12(24):3245-3258
9. Witton CJ, Reeves JR, Going JJ et al (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200(3):290-297
10. Kim MJ, Ro JY, Ahn SH et al (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37(9):1217-1226
11. Borg A, Baldetorp B, Ferno M et al (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144
12. Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97(17):1254-1261
13. Stål O, Borg A, Ferno M et al (2000) ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11:1545-1550
14. De Placido S, De Laurentiis M, Carlomagno C et al (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9(3):1039-1046
15. Dowsett M, Houghton J, Iden C et al (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17(5):818-826
16. Dowsett M, Cuzick J, Wale C et al (2005) Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23(30):7512-7517
17. Ellis MJ, Tao Y, Young O et al (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24(19):3019-3025
18. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792
19. Pegram MD, Pienkowski T, Northfelt DW et al (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96(10):759-769
20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659-1672
21. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11(18):6598-6607
22. Ryden L, Jonsson PE, Chebil G et al (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41(2):256-264
23. Knoop AS, Bentzen SM, Nielsen MM et al (2001) Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19(14):3376-3384
24. Love RR, Duc NB, Havighurst TC et al (2003) Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21(3):453-457
25. Ryden L, Jirstrom K, Bendahl PO et al (2005) Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23(21):4695-4704
26. Huang HJ, Neven P, Drijkoningen M et al (2005) Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 91(1):81-87